Genmab A/S: Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

Preliminary analysis of data from the EPCORE NHL-2 study demonstrates patients with previously untreated follicular lymphoma (FL) who received epcoritamab in combination with rituximab-lenalidomide

Related Keywords

United States ,Japan ,Boston ,Massachusetts ,Chicago ,Illinois ,Denmark ,Copenhagen ,Køavn ,Canada ,American ,America ,Judith Klimovsky ,Hematol Hemoter ,Asia Pacific ,Joshua Brody ,David Freundel ,Andrew Carlsen ,Drug Administration ,Lymphoma Research Foundation ,Leukemia Lymphoma Society ,Genmab Us Inc ,American Society Of Clinical Oncology ,Linkedin ,Global Communications Corporate Affairs ,Data From The Observational National Lymphocare Study ,Exchange Commission ,Abbvie Biotechnology Ltd ,Clinical Oncology ,Annual Meeting ,Mount Sinai Hess Center ,Priority Review ,Biologics License Application ,Follicular Lymphoma ,Medication Guide ,North America ,Media Release ,Annual Report ,Y Shaped Genmab ,Abbvie Biotechnology ,Opin Med ,Leukemia Lymphoma ,Accessed March ,Subsequent Therapy ,Data From ,Observational National Lymphocare ,Treatment Patterns ,Patients With Diffuse Largeb Cell Lymphoma ,Bras Hematol ,Relapsed Follicular Lymphoma ,Marginal Zone Lymphoma ,Senior Director ,Vice President ,Investor Relations ,Ihr Portfolio ,